Welcome to our dedicated page for OMNICELL SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Omnicell, Inc. filings document financial results, guidance updates, governance matters, and capital-plan items for a Nasdaq-listed healthcare technology company focused on medication management. Form 8-K reports furnish quarterly and annual operating results and record material events such as executive appointments and amendments to bylaws.
Proxy materials describe annual meeting proposals, director elections, executive compensation votes, equity incentive plan authorization, certificate of incorporation amendments, auditor ratification, and related stockholder voting mechanics. These filings also provide formal disclosure around Omnicell’s common stock governance, board oversight, and stockholder rights provisions.
The Vanguard Group filed an amendment to its Schedule 13G/A reporting 0% beneficial ownership of Omnicell Inc. common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries and business divisions will report holdings separately in reliance on SEC Release No. 34-39538. The amendment, signed on March 27, 2026, lists 0 shares beneficially owned and 0% of the class, with no sole or shared voting or dispositive power.
Omnicell, Inc. Chairman, President and CEO Randall A. Lipps reported vesting of 79,494 performance-based restricted stock units of Common Stock. These RSUs were originally granted on March 15, 2025 and became earned after the company met stock performance objectives versus the S&P 1000 Healthcare Index, with 25% vesting on the one-year anniversary of the grant.
In connection with this vesting, 15,642 shares were withheld at $34.40 per share to cover tax liabilities, leaving 444,592 Common Stock shares held directly after the transactions. Separate from his direct holdings, 355,861 shares are held in a trust with his wife and 8,051 shares are held in a trust for his children.
Omnicell EVP and COO Nnamdi Njoku reported equity compensation changes tied to performance-based restricted stock units. He acquired 37,409 common shares at no cost upon vesting of previously granted performance-based RSUs after the company met stock performance objectives versus the S&P 1000 Healthcare Index.
Of these vested shares, 8,456 were withheld to cover taxes at a price of $34.40 per share. Following these transactions, Njoku directly holds 115,239.4457 shares of Omnicell common stock. The remaining performance-based RSUs will vest in equal quarterly installments over three years.
Omnicell EVP and Chief Legal/Admin Officer Corey J. Manley reported equity compensation vesting and related share transactions. On March 15, 2026, he acquired 22,445 shares of Common Stock at $0.00 per share as a grant tied to performance-based restricted stock units previously awarded on March 15, 2025.
On the same date, 3,819 shares were withheld at $34.40 per share to cover taxes due upon vesting of these restricted stock units. On March 16, 2026, he sold 7,405 shares in an open-market transaction at an exact price of $34.69 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025.
Following these transactions, Manley directly held 96,717.3392 shares of Omnicell Common Stock. The remaining performance-based restricted stock units from the March 2025 grant will vest in equal quarterly increments every three months over a three-year period, on each May 15, August 15, November 15, and February 15.
OMCL filed a Form 144 reporting proposed sales of Common Stock and recent affiliate dispositions. The notice lists a restricted stock vesting of 7,405 shares on 03/15/2026 associated with compensation. The filing also discloses prior affiliate sales by Corey Manley of 278 shares on 12/16/2025 for $12,037.40, 6,106 shares on 01/08/2026 for $304,689.40, and 4,243 shares on 02/17/2026 for $155,251.37.
Omnicell, Inc. is a healthcare technology company focused on autonomous medication management across hospitals, health systems, and outpatient pharmacies. The company combines dispensing automation, robotics, and its cloud-based intelligence ecosystem, OmniSphere, to improve safety, labor efficiency, and financial outcomes from central pharmacy to bedside and retail settings.
Omnicell organizes offerings into hospital and health system solutions, outpatient pharmacy solutions, specialty and 340B services, institutional and retail pharmacy support, and patient engagement under its EnlivenHealth brand. In 2024, U.S. prescription drug spending reached $806 billion, with specialty drugs at 51.7% of expenditures, trends Omnicell believes support long-term demand for automation and analytics.
The company generated approximately 90% of its 2025 revenue in the United States and reported total product backlog of $640.3 million as of December 31, 2025, including long-term backlog expected to convert over 12–24 months. Omnicell employed about 3,580 people worldwide and emphasizes ESG initiatives, workforce development, and a “Culture of Care” as strategic priorities.
Omnicell VP and Chief Accounting Officer Brian H. Nutt reported routine equity transactions involving company common stock. On February 15, 2026, 258 shares were disposed of to cover tax withholding tied to vesting restricted stock units. The reported balance also reflects 445.6135 shares purchased that day under Omnicell's Employee Stock Purchase Plan, bringing his direct holdings to 17,529.6135 shares.
Omnicell EVP and COO Nnamdi Njoku reported a tax-related share disposition. On February 15, 2026, 1,146 shares of Omnicell common stock were withheld at $36.50 per share to cover taxes due on vesting restricted stock units, rather than being sold in the open market.
After this withholding and an additional 239.4457 shares purchased under the company’s Employee Stock Purchase Plan on February 15, 2026, Njoku’s direct holdings total 86,286.4457 shares of Omnicell common stock.
Omnicell, Inc. executive Corey J. Manley reported share dispositions. He sold 4,243 shares of common stock in an open-market transaction at an exact price of $36.59 per share under a Rule 10b5-1 trading plan adopted on June 13, 2025.
Separately, 2,022 shares were withheld to cover taxes due on the vesting of restricted stock units, which is a tax-withholding disposition rather than an open-market sale. After these transactions and the purchase of 87.3392 shares under the Employee Stock Purchase Plan on February 15, 2026, he directly owned 85,496.3392 shares.
OMNICELL, INC. Chairman, President and CEO Randall A. Lipps reported a tax-withholding disposition of 5,294 shares of common stock on February 15, 2026. The shares were withheld at a price of $36.50 per share to cover taxes due on vesting restricted stock units.
After this transaction, Mr. Lipps directly owned 380,740.0741 shares of Omnicell common stock. He also reported indirect holdings of 355,861 shares held in trust with his wife and 8,051 shares held in trust for the benefit of his children.